Hexylene Glycol
CAS 107-41-5
Hexylene Glycol (CAS 107-41-5) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 19976.309999999998 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| HEXYLENE GLYCOL | 1305548 | SU | MTHSPL |
| Hexylene Glycol | 1305548 | SU | MTHSPL |
| hexylene glycol | 1305548 | SU | MTHSPL |
| hexylene glycol | 1305548 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Hexylene Glycol used for in pharmaceutical contexts?
Hexylene Glycol (CAS 107-41-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Hexylene Glycol?
No adverse-event association or SIDER side-effect rows are rendered for Hexylene Glycol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Hexylene Glycol also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Hexylene Glycol.
What clinical phase is Hexylene Glycol in?
No phase 1-4 clinical development badge is rendered for Hexylene Glycol because the matched compound identifier rows do not contain a max-phase value.